Boehringer flags PhI­II suc­cess for an­oth­er Hu­mi­ra knock­off, set­ting up a crowd­ed field of cheap­er ri­vals — even­tu­al­ly

You can count one more like­ly Hu­mi­ra biosim­i­lar in the grow­ing crowd of ri­vals look­ing to tack­le Ab­b­Vie’s $14 bil­lion fran­chise.

Ger­many’s Boehringer In­gel­heim has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.